Legal Representation
Attorney
Jared M. Barrett
USPTO Deadlines
Application History
22 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 29, 2024 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Jul 29, 2024 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Dec 16, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 14, 2023 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Dec 14, 2023 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Dec 14, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 29, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jun 27, 2023 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Jun 27, 2023 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Jun 27, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Dec 27, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 23, 2022 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Dec 23, 2022 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Dec 23, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 28, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| May 3, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| May 3, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Apr 13, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Mar 29, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Mar 28, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 27, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 1, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
pharmaceutical preparations for the treatment of kidney disease; pharmaceutical preparations for the treatment of focal segmental glomerulosclerosis (FSGS); pharmaceutical preparations for the treatment of Immunoglobulin A Nephropathy (IgAN); pharmaceutical preparations for the treatment of Alport Syndrome; pharmaceutical preparations for the treatment of glomerulonephropathy; pharmaceutical preparations for the treatment of glomerulonephritis
Classification
International Classes
005